Owen A O'Connor -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
John Wright -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
Craig Moskowitz -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
Jamie Muzzy -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
Barbara MacGregor-Cortelli -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
Michael Stubblefield -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
David Straus -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
Carol Portlock -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
Paul Hamlin -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
Elizabeth Choi -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
Otila Dumetrescu -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
Dixie Esseltine -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
Elizabeth Trehu -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
Julian Adams -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
David Schenkein -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
Andrew D Zelenetz -
From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD
